Abiraterone Tablets
Developed to target prostate cancer progression, this medication is utilized to alleviate hormonal signals that support tumour growth.
- Category
- Oncology Support
- Active ingredient
- Abiraterone
- Supply
- Rx
- Route
- Oral use
- Form
- Tablet; Film-coated tablet
- Strengths
- 250mg
Abiraterone Tablets details
- Condition
- Prostate Cancer
- Alternative names
- Zytiga
- Therapeutic class
- Antiandrogen
- Pharmacological class
- CYP17A1 Inhibitor
- Contraindications
- hypersensitivity to abiraterone; severe hepatic impairment; pregnancy
- Minor side effects
- oedema; fatigue; hypertension
- Moderate side effects
- hypokalaemia; elevated liver enzymes
- Dosage forms
- Tablet; Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Janssen-Cilag
- Onset Time
- 2 hours
- Duration
- 24 hours
- Storage instructions
- Store below 30°C.
- Drug interactions
- corticosteroids; CYP3A4 inducers
- Age restrictions
- Not for use in women or children.
Precautions and warnings
monitor liver function tests; monitor blood pressure; monitor potassium levels; maintain regular corticosteroid intake
Serious side effects
adrenocortical insufficiency, requires immediate medical attention; myopathy, requires immediate medical attention
Patient summary
Developed to target prostate cancer progression, this medication is utilized to alleviate hormonal signals that support tumour growth.
Mechanism of action
This medicine is a selective inhibitor of the enzyme CYP17A1. By blocking this enzyme, it prevents the synthesis of androgens in the adrenal glands and testes, reducing testosterone levels which can fuel the progression of certain prostate cancers.
Pregnancy and breastfeeding
Pregnancy: Must strictly be avoided by women who are pregnant or may become pregnant.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Abiraterone Tablets
Abiraterone Tablets contain the active ingredient abiraterone, a well-known medication used to manage prostate cancer. This compound is widely recognized by the original brand name Zytiga. It is supplied as oral tablets in the 250mg strength, a standard concentration for this type of treatment.
Abiraterone Tablets availability in Asia
Abiraterone Tablets are registered across 14 markets including Thailand, Malaysia and the Philippines, with availability also in Indonesia, Taiwan and South Korea. Generic abiraterone, much of it manufactured in India, is far more affordable than the original Zytiga from Janssen-Cilag. This medication is best used under a doctor’s care.